Qualitative interviews reveal pain with intramuscular fulvestrant in HER2- breast cancer, suggesting oral options provide convenience.
Patients with ER+ HER2- ABC in this study preferred oral to IM ET owing to convenience, and disliked the pain associated with IM ET and travel to receive injections. Compared to IM fulvestrant, oral SERDs may offer an alternative with less burden on the lives of people living with cancer.
No takes yet. Share an insight, caveat, or question.
Harding et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: